Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

Circulation

Volumn 103, Issue 15, 2001, Pages 1942-1948

  März, Winfried ^a,b,c   Scharnagl, Hubert ^a,b   Abletshauser, Claudia ^a,b   Hoffmann, Michael M ^a,b   Berg, Aloys ^a,b   Keul, Joseph ^a,b   Wieland, Heinrich ^a,b   Baumstark, Manfred W ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Novartis Pharma AG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Coronary disease; Fluvastatin; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035901584     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.15.1942     Document Type: Article

References (44)

1. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: Normalization after clofibrate treatment
2. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor
3. Small dense low density lipoprotein has increased affinity for LDL-receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity
4. Low density lipoprotein subclass patterns and risk of myocardial infarction
5. Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease
6. Low density lipoprotein particle size and coronary artery disease
7. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women
8. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
9. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
10. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
11. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study
12. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians: The Strong Heart Study
13. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)
14. Endothelial dysfunction in men with small LDL particles
15. The effect of lovastatin on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia
16. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia
17. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia
18. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia
19. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern
20. Pravastatin treatment in combined hyperlipidaemia: Effect on plasma lipoprotein levels and size
21. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability
22. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia
23. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease
24. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans
25. Effect of fluvastatin on low-density lipoprotein peak particle diameter
26. Fluvastatin: A review of its use in lipid disorders
27. Structure of human low-density lipoprotein subfractions, determined by x-ray small-angle scattering
28. Improved assessment of plasma lipoprotein patterns, IV: Simple preparation of a lyophilized control serum containing intact human plasma lipoproteins
29. Preparative ultracentrifuge laboratory procedures and suggestions for lipoprotein analysis
30. Change in LDL particle size is associated with change in plasma triglyceride concentration
31. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies
32. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia
33. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia
34. Differential effects of nicotinic acid in subjects with different LDL subclass patterns
35. Lipids and risk of coronary heart disease: The Framingham Study
36. Effects of simvastatin on apoB metabolism and LDL subfraction distribution
37. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells
38. The metabolism of very-low-density and intermediate-density lipoproteins in patients with familial hypercholesterolemia
39. Lipoprotein heterogeneity and apolipoprotein B metabolism
40. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease
41. Determinants of low-density lipoprotein subfraction distribution and concentrations in young normolipidemic subjects
42. Relations between plasma lipids and postheparin plasma lipases and VLDL subfractions in normolipidemic men and women
43. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia
44. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclass, and postprandial lipemia